A Multi-center, Randomized, Observer-blind, Placebo-controlled Safety and Tolerability Study of Repeated Administration of two dose levels of RO4989991 Administered Subcutaneously to Patients with Allergic Rhinitis
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Oxelumab (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
- Sponsors Roche
- 17 Jan 2012 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 17 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2011 Planned end date changed from 1 Jan 2011 to 1 May 2011 as reported by ClinicalTrials.gov.